Literature DB >> 31618063

Intermittent hypoxia and hypercapnia induces inhibitor of nuclear factor-κB kinase subunit β-dependent atherosclerosis in pulmonary arteries.

Toshihiro Imamura1, Jin Xue1, Orit Poulsen1, Dan Zhou1, Michael Karin2,3, Gabriel G Haddad1,4,5.   

Abstract

Clinical studies have shown that obstructive sleep apnea (OSA) increases atherosclerosis risk. The inflammation, especially mediated by the macrophages via nuclear factor-κB (NF-κB), has been speculated to contribute to atherogenicity in OSA patients. Inhibitor of NF-κB kinase-β (IKKβ) is an essential element of the NF-κB pathway and is linked to atherosclerosis. We previously reported that atherosclerosis was accelerated in pulmonary artery (PA) but not in aorta when low-density lipoprotein receptor knockout (Ldlr-/-) mice were exposed to intermittent hypoxia/hypercapnia (IHH), a surrogate for recurrent upper-airway obstruction. Therefore, we hypothesized that IKKβ-dependent NF-κB activation in monocytes and macrophages plays a role in IHH-induced PA atherosclerosis. To test this hypothesis, myeloid restricted IKKβ deletion (IkkβΔMye) or control (IkkβF/F) mice were crossed with Ldlr-/- mice to generate double-knockout mice. Then, the mice were exposed to IHH or room air (Air) on high-fat diet for 8 or 16 wk. Lesions of PA and aorta were examined in IkkβΔMye;Ldlr-/- and IkkβF/F;Ldlr-/- male mice under IHH vs. Air. The results revealed that IKKβ deletion abolished IHH-induced PA atherosclerosis after 8-wk exposure but not after 16-wk exposure (8 wk: IkkβF/F;Ldlr-/-, IHH 13.5 ± 1.4 vs. Air 5.7 ± 0.7%, P < 0.01; IkkβΔMye;Ldlr-/-, IHH 7.4 ± 1.9% vs. Air 4.6 ± 1.3%, P = 0.24). Both IKKβ deletion and IHH had no effects on atherosclerosis in the aorta. Our findings demonstrate that IKKβ-dependent NF-κB activity in myeloid-lineage cells plays a critical role in IHH-induced PA atherosclerosis at the early stage.

Entities:  

Keywords:  atherosclerosis; intermittent hypoxia and hypercapnia; nuclear factor-κB; obstructive sleep apnea; pulmonary artery

Year:  2019        PMID: 31618063      PMCID: PMC6962627          DOI: 10.1152/ajpregu.00056.2019

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  45 in total

Review 1.  Obstructive sleep apnea: an emerging risk factor for atherosclerosis.

Authors:  Luciano F Drager; Vsevolod Y Polotsky; Geraldo Lorenzi-Filho
Journal:  Chest       Date:  2011-08       Impact factor: 9.410

Review 2.  JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction.

Authors:  Giovanni Solinas; Michael Karin
Journal:  FASEB J       Date:  2010-04-06       Impact factor: 5.191

3.  Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.

Authors:  Jose M Marin; Santiago J Carrizo; Eugenio Vicente; Alvar G N Agusti
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

4.  Regression of atherosclerosis in cholesterol-fed rabbits: effects of fish oil and verapamil.

Authors:  B Q Zhu; R E Sievers; W M Isenberg; D L Smith; W W Parmley
Journal:  J Am Coll Cardiol       Date:  1990-01       Impact factor: 24.094

5.  IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.

Authors:  Florian R Greten; Lars Eckmann; Tim F Greten; Jin Mo Park; Zhi-Wei Li; Laurence J Egan; Martin F Kagnoff; Michael Karin
Journal:  Cell       Date:  2004-08-06       Impact factor: 41.582

Review 6.  Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome.

Authors:  Luciano F Drager; Sônia M Togeiro; Vsevolod Y Polotsky; Geraldo Lorenzi-Filho
Journal:  J Am Coll Cardiol       Date:  2013-06-12       Impact factor: 24.094

7.  Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis.

Authors:  Claudia Monaco; Evangelos Andreakos; Serafim Kiriakidis; Claudia Mauri; Colin Bicknell; Brian Foxwell; Nicholas Cheshire; Ewa Paleolog; Marc Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-02       Impact factor: 11.205

8.  Association between obstructive sleep apnea and pulmonary embolism.

Authors:  Alberto Alonso-Fernández; Mónica de la Peña; David Romero; Javier Piérola; Miguel Carrera; Antonia Barceló; Joan B Soriano; Angela García Suquia; Carmen Fernández-Capitán; Alicia Lorenzo; Francisco García-Río
Journal:  Mayo Clin Proc       Date:  2013-04-08       Impact factor: 7.616

9.  Pulmonary artery atherosclerosis: correlation with systemic atherosclerosis and hypertensive pulmonary vascular disease.

Authors:  G W Moore; R R Smith; G M Hutchins
Journal:  Arch Pathol Lab Med       Date:  1982-08       Impact factor: 5.534

Review 10.  Chronic intermittent hypoxia and obstructive sleep apnea: an experimental and clinical approach.

Authors:  Emilia Sforza; Fréderic Roche
Journal:  Hypoxia (Auckl)       Date:  2016-04-27
View more
  3 in total

1.  A longitudinal 18F-fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (18F-NaF) positron emission tomography/computed tomography (PET/CT) study in apolipoprotein E (ApoE) knockout rats fed with a Western diet.

Authors:  Xiaoqing Zhuang; Yue Feng; Juan Li; Feng Zhao; Yu Zhang; Yue Chen
Journal:  Cardiovasc Diagn Ther       Date:  2021-02

2.  Influence of Intermittent Hypoxia/Hypercapnia on Atherosclerosis, Gut Microbiome, and Metabolome.

Authors:  Jin Xue; Celeste Allaband; Dan Zhou; Orit Poulsen; Cameron Martino; Lingjing Jiang; Anupriya Tripathi; Emmanuel Elijah; Pieter C Dorrestein; Rob Knight; Amir Zarrinpar; Gabriel G Haddad
Journal:  Front Physiol       Date:  2021-04-08       Impact factor: 4.755

3.  Effects of Normoxic Recovery on Intima-Media Thickness of Aorta and Pulmonary Artery Following Intermittent Hypoxia in Mice.

Authors:  Akira Umeda; Kazuya Miyagawa; Atsumi Mochida; Hiroshi Takeda; Kotaro Takeda; Yasumasa Okada; David Gozal
Journal:  Front Physiol       Date:  2020-10-22       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.